Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 00093-1135
Product Overview
NDC 00093-1135 corresponds to ABRAXANE (paclitaxel protein-bound particles for injectable suspension) manufactured by Celgene/Bristol-Myers Squibb. Approved for multiple indications, including metastatic pancreatic cancer, non-small cell lung cancer, and breast cancer, it is a cornerstone in oncological treatment protocols.
Market Landscape
Market Size
The global paclitaxel market, including branded formulations like ABRAXANE, reached approximately $1.5 billion in 2022[1]. ABRAXANE accounts for roughly 30-40% of this sales, driven by its use across multiple indications and favorable safety profile compared to traditional paclitaxel.
Key Competitors
- Generic paclitaxel formulations—massive market share, lower prices.
- Other branded formulations: Taxol (figures for non-protein-bound paclitaxel), with a smaller segment in niche indications.
- Emerging therapies: Liposomal and nanoparticle-based chemotherapies targeting similar cancers.
Distribution Channels
- Oncology clinics and hospitals dominate sales.
- Reimbursement depends on national healthcare policies; in the U.S., Medicare and private insurers cover most expenses.
Regulatory Environment
- FDA approval since 2012.
- Patent protections mainly expired or nearing expiration; exclusivity up to early 2024 in the U.S., with some patent extensions.
Pricing Trends and Projections
Current Pricing
- Per-vial cost: Ranges between $3,500 and $6,000 for a typical dose (100 mg vial).
- Average wholesale price (AWP) for ABRAXANE is approximately $4,500 per 100 mg vial.
- Treatment courses for metastatic cancers involve multiple vials, driving significant cumulative costs.
Price Trends
- Post-2012 introduction, ABRAXANE maintained prices with slight increases (3-5% annually).
- Patent expiration and biosimilar entry from 2024 likely exert downward pressure.
- Reimbursement policies in key markets influence retail pricing, with pricing discounts often negotiated by payers.
Price Projections
- Short-term (2023-2024): Prices remain stable, assuming no immediate biosimilar competition; projected price per vial remains around $4,500.
- Mid-term (2024-2026): Biosimilar entry could reduce prices by 20-40%; forecasted price per vial may decline to $3,000–$3,600.
- Long-term (post-2026): Market consolidation and new therapies may further influence prices; potential stabilization around $2,500–$3,000 per vial if biosimilar adoption grows.
Volume and Revenue Projections
- In 2022, estimated annual sales were $450–$600 million.
- Growth primarily driven by rising cancer incidence and expanded indications.
- Before biosimilar entry, projected growth rate is 2-4% annually.
- Post-biosimilar introduction, a decline of 15-30% in sales expected in the next 3-5 years, with potential for market share shifts to generics.
Key Factors Impacting Prices and Market Share
- Patent and exclusivity expiry.
- Biosimilar approvals in major markets (FDA, EMA, China).
- Healthcare policies influencing reimbursement.
- Clinical efficacy and safety, which maintain ABRAXANE’s pricing power.
- Adoption of new therapies or combination regimens influencing demand.
Key Takeaways
- NDC 00093-1135 (ABRAXANE) dominates a $1.5 billion market segmented mainly across oncology.
- Pricing remains stable at around $4,500 per vial but is subject to decline with biosimilar entry.
- Biosimilars are expected to cut prices by up to 40%, potentially restructuring the market.
- Revenue declines are projected beginning in 2024, with market share shifting towards generic forms.
- Ongoing patent expirations and regulatory approvals will shape future pricing and market dynamics.
FAQs
Q1: When will biosimilars for ABRAXANE become available?
A1: Biosimilars are expected to gain approval starting 2024, with market entry likely within 1-2 years after approval.
Q2: How do biosimilars typically impact drug prices?
A2: Biosimilars usually reduce prices by 20-40%, depending on market uptake and competition.
Q3: What are the main indications driving ABRAXANE sales?
A3: Metastatic pancreatic cancer, non-small cell lung cancer, and breast cancer.
Q4: How does reimbursement policy influence ABRAXANE pricing?
A4: Reimbursement rates directly impact net prices paid by healthcare providers; stricter policies can lead to discounts.
Q5: Are there ongoing clinical trials that could affect ABRAXANE's market position?
A5: Yes, trials evaluating combination therapies and new indications could expand or cannibalize existing sales.
References
- MarketWatch, “Paclitaxel Market Size, Share & Trends Analysis Report 2022-2030,” 2022.
- U.S. FDA, “ABRAXANE (paclitaxel protein-bound particles for injectable suspension) approval history,” 2012.
- EvaluatePharma, “Oncology Drugs and Biosimilars Price Trends,” 2023.
- IQVIA, “Global Oncology Market Data,” 2022.
[1] MarketWatch.
